Breast Cancer Lymphedema: Role of Insulin Resistance/FOXC2

Not Recruiting

Trial ID: NCT00383604


To better understand the mechanisms leading to lymphedema development in breast cancer survivors, and the implications for potential innovative approaches to the screening, prevention and treatment of this condition.

Official Title

Breast Cancer Lymphedema: Role of Insulin Resistance/FOXC2

Stanford Investigator(s)

Stanley G. Rockson, MD
Stanley G. Rockson, MD

Allan and Tina Neill Professor of Lymphatic Research and Medicine


Inclusion Criteria:

* Patients enrolled in the proposed studies must be survivors of breast cancer at a time point at least 4 years following the initial surgery and radiotherapy for the disease.
* Patients must have a history of unilateral axillary lymph node dissection.
* Patients referred to, or that receive their care within the Stanford University Breast Cancer Program and the Stanford Center for Lymphatic and Venous Disorders.
* Patients will be required to have the capacity to provide informed consent.

Exclusion Criteria:

* Patients with other serious systemic illness (renal failure, hepatic dysfunction, congestive heart failure, neurological or psychological impairment) that would confound the study or impair the patients' ability to participate.
* Patients will not be enrolled if they are taking drugs that affect carbohydrate metabolism.
* Patients with recurrent breast cancer or other forms of pre-existing lymphedema will be ineligible.

Not Recruiting

Contact Information

Stanford University
School of Medicine
300 Pasteur Drive
Stanford, CA 94305
Anne Marie Vaillant-Newman

New Trial Alerts